ATLANTA, GA – – (Globe Newswire – April 18, 2023) – – Holzer & Holzer, LLC is investigating whether Alvotech (“Alvotech” or the “Company”) (NASDAQ: ALVO) complied with federal securities laws. On April 13, 2023, Alvotech disclosed that the FDA “issued a complete response letter (“CRL”) for Alvotech’s Biologics License Application” which noted certain deficiencies and stated that the FDA requires the deficiencies to be “satisfactorily resolved before the application can be approved.” Following this news, the price of the Company’s stock dropped.
If you purchased Alvotech stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, call our toll-free number at (888) 508-6832, or visit our website at https://holzerlaw.com/case/alvotech/ to discuss your legal rights.